Trial Profile
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- 04 Jan 2023 Status changed from recruiting to discontinued.
- 02 Feb 2022 Planned End Date changed from 1 Aug 2021 to 31 Dec 2022.
- 02 Feb 2022 Planned primary completion date changed from 1 Aug 2021 to 31 Dec 2022.